Literature DB >> 16601980

Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c).

Katharina E Schmid1, Beatrix Neumaier-Ammerer, Ulrike Stolba, Susanne Binder.   

Abstract

BACKGROUND: Glycosylated haemoglobin (HbA1c) correlates with the amount of hyperglycemia in diabetic patients. High HbA1c levels often predict clinically significant macular edema (CSME), which then needs to be treated with grid laser photocoagulation. The question asked in this study was whether there is a correlation between the effect grid laser photocoagulation in diffuse diabetic macular edema and HbA1c, using an optical coherence tomography (OCT) for the evaluation of the retinal thickness.
METHODS: A prospective, non-comparative case series was performed to find a correlation between the effect of grid laser photocoagulation in diffuse diabetic macular edema and HbA1c. Thirty eyes with CSME of diabetic patients were included in the study. Complete ophthalmic examinations and OCT were performed at baseline, 1 month, 3, and 6 months after grid laser photocoagulation therapy. HbA1c was measured at the end of study.
RESULTS: Significance level was set at P<0.05. A significant difference in the foveal (P=0.02) and superior (P=0.021) retinal thickness 6 months after laser therapy, no correlation between HbA1c and retinal thickness after photocoagulation, and an insignificant decrease in visual acuity (P=0.9) were found. The correlation between foveal retinal thickness and visual acuity was P=0.24 6 months after treatment.
CONCLUSION: There was no significant correlation between HbA1c and the effect of grid laser photocoagulation therapy in diffuse diabetic macular edema. The retinal thickness decreased significantly in the foveal and superior area 6 months after therapy. No correlation between the foveal retinal thickness and the visual acuity was found. The visual acuity did not increase after treatment. There are many factors influencing the retinal thickness, such as the blood pressure and the attached posterior hyaloid.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601980     DOI: 10.1007/s00417-006-0322-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  45 in total

1.  Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema.

Authors:  R J Olk
Journal:  Ophthalmology       Date:  1990-09       Impact factor: 12.079

2.  The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema.

Authors:  Se Woong Kang; Choul Yong Park; Don-Il Ham
Journal:  Am J Ophthalmol       Date:  2004-02       Impact factor: 5.258

3.  A comparison of retinal morphology viewed by optical coherence tomography and by light microscopy.

Authors:  C A Toth; D G Narayan; S A Boppart; M R Hee; J G Fujimoto; R Birngruber; C P Cain; C D DiCarlo; W P Roach
Journal:  Arch Ophthalmol       Date:  1997-11

4.  Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

5.  The interpretation of optical coherence tomography images of the retina.

Authors:  D S Chauhan; J Marshall
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

6.  Diabetic maculopathy. A critical review highlighting diffuse macular edema.

Authors:  G H Bresnick
Journal:  Ophthalmology       Date:  1983-11       Impact factor: 12.079

7.  Use of optical coherence tomography (OCT) and indirect ophthalmoscopy in the diagnosis of macular edema in diabetic patients.

Authors:  R O Moreira; F R Trujillo; R M Meirelles; V C Ellinger; L Zagury
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

8.  Temporal variation in diabetic macular edema measured by optical coherence tomography.

Authors:  Robert N Frank; Laura Schulz; Kyohei Abe; Raymond Iezzi
Journal:  Ophthalmology       Date:  2004-02       Impact factor: 12.079

9.  Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy.

Authors:  J Sebag; B Buckingham; M A Charles; K Reiser
Journal:  Arch Ophthalmol       Date:  1992-10

10.  Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results.

Authors:  C M Lee; R J Olk
Journal:  Ophthalmology       Date:  1991-10       Impact factor: 12.079

View more
  5 in total

1.  Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.

Authors:  Mohammad Riazi-Esfahani; Hamid Riazi-Esfahani; Aliasghar Ahmadraji; Reza Karkhaneh; Alireza Mahmoudi; Ramak Roohipoor; Fariba Ghasemi; Mehdi Yaseri
Journal:  Int Ophthalmol       Date:  2017-03-27       Impact factor: 2.031

2.  Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Heshmatollah Ghanbari; Farzan Kianersi; Seyed Ali Sonbolestan; Mohammad-Ali Abtahi; Mojataba Akbari; Zahra-Alsadat Abtahi; Seyed-Hossein Abtahi
Journal:  Int Ophthalmol       Date:  2016-09-13       Impact factor: 2.031

Review 3.  Diabetic macular edema: what is focal and what is diffuse?

Authors:  David J Browning; Michael M Altaweel; Neil M Bressler; Susan B Bressler; Ingrid U Scott
Journal:  Am J Ophthalmol       Date:  2008-09-05       Impact factor: 5.258

4.  Correlation Between the Findings of Optical Coherent Retinal Tomography (OCT), Stereo Biomicroscopic Images from Fundus of an Eye and Values from Visual Acuity of Diabetic Macular Edema.

Authors:  Faruk Nisic; Samir Turkovic; Milka Mavija; Nina Jovanovic; Emina Halilovic- Alimanovic
Journal:  Acta Inform Med       Date:  2014-08-21

5.  Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children.

Authors:  Katarzyna Zorena; Jolanta Myśliwska; Małgorzata Myśliwiec; Anna Balcerska; Łukasz Hak; Paweł Lipowski; Krystyna Raczyńska
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.